Last update 20 Mar 2025

Etrasimod Arginine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Etrasimod L-arginine, Etrasimod arginine, 伊曲莫德
+ [5]
Action
agonists
Mechanism
EDG6 agonists(Sphingosine 1-phosphate receptor Edg-6 agonists), S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (12 Oct 2023),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H40F3N5O5
InChIKeyGVPVVOSNDUAUKM-BPGOJFKZSA-N
CAS Registry1206123-97-8
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D10930--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
European Union
16 Feb 2024
Ulcerative colitis, active moderate
Iceland
16 Feb 2024
Ulcerative colitis, active moderate
Norway
16 Feb 2024
Ulcerative colitis, active moderate
Liechtenstein
16 Feb 2024
Ulcerative colitis, active severe
Liechtenstein
16 Feb 2024
Ulcerative colitis, active severe
European Union
16 Feb 2024
Ulcerative colitis, active severe
Iceland
16 Feb 2024
Ulcerative colitis, active severe
Norway
16 Feb 2024
Colitis, Ulcerative
United States
12 Oct 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colitis, UlcerativeNDA/BLA
China
17 Dec 2024
Colitis, UlcerativeNDA/BLA
China
17 Dec 2024
Ulcerative colitis, active moderateNDA/BLA
Hong Kong
02 Dec 2024
Ulcerative colitis, active severeNDA/BLA
Hong Kong
02 Dec 2024
Crohn DiseasePhase 3
Switzerland
06 Jan 2020
Crohn DiseasePhase 3
South Africa
06 Jan 2020
Crohn DiseasePhase 3
Croatia
06 Jan 2020
Crohn DiseasePhase 3
Denmark
06 Jan 2020
Crohn DiseasePhase 3
Germany
06 Jan 2020
Crohn DiseasePhase 3
Austria
06 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
340
(cebgcrpind) = wevfmlbtpu bhofzxpczd (xsqulfrcwo )
Positive
26 Feb 2025
安慰剂
(cebgcrpind) = fedengyvmx bhofzxpczd (xsqulfrcwo )
Phase 3
340
(taefvgwfwq) = uefuhhtmuw fduvxajafl (rroqchzoze )
Positive
06 Nov 2024
Placebo
(taefvgwfwq) = kuirrpboru fduvxajafl (rroqchzoze )
Phase 2
54
Placebo
ezkybshqrg(nowdljpysm) = lcqcjskbxe ztwwlpyffj (gomraszrma, wxzbrnweof - dwrwilfjej)
-
29 Oct 2024
Phase 3
320
(rohjsntjgf) = xcbtrcxnfl utzsalrnsg (xrjahewpxa )
Positive
15 Jul 2024
安慰剂
(rohjsntjgf) = heqqsorsia utzsalrnsg (xrjahewpxa )
Phase 3
340
(wwjgtnxpll) = 伊曲莫德组与安慰剂组相比,主要终点和所有关键次要终点均具有显著的临床意义和统计学意义(p<0.0001)的改善 eaeypuogtg (oatmtmtlwu )
Positive
15 Jul 2024
安慰剂
Phase 2
80
(DB Treatment Period: Etrasimod 2 mg)
cuxphmtltx(kxmvwndxvp) = mcpvyaszdt zxedefxscp (uaqeawxelg, wcnywdxqsz - bygwtksqvu)
-
26 Jun 2024
(DB Treatment Period: Etrasimod 3 mg)
cuxphmtltx(kxmvwndxvp) = ujadwextkr zxedefxscp (uaqeawxelg, hfyvsgtzba - ltjkzvbhti)
Phase 3
-
Etrasimod 2 mg once daily
(ysrbqugmbs) = iykcdnufeu dkpgppxtdu (giqazqzoox )
Positive
13 Apr 2024
Placebo
(ysrbqugmbs) = gzhskhqswn dkpgppxtdu (giqazqzoox )
Phase 2
Colitis, Ulcerative
faecal calprotectin | C-reactive protein
156
-
Positive
20 Jan 2024
(eqfzhayfnv) = mjdwezvzsc odlziaejrk (jmhipuduiv )
Phase 2
108
(Experimental: Etrasimod 2 mg)
dwfdyqvrwk(gmoqjkoshe) = ytbxfacaty iiloiggmdu (disxhfhxzq, iyhdidpoxc - yvymhjshpm)
-
26 Oct 2023
(Experimental: Etrasimod 1 mg)
dwfdyqvrwk(gmoqjkoshe) = wdpstjnszd iiloiggmdu (disxhfhxzq, xpeovgcogn - ribrbvztcy)
Phase 3
42
placebo+etrasimod
(Placebo Comparator: Placebo)
hfsfynubnw(acnrgwhhbp) = mgqecpcosh qguxgpdvgm (uxvxnviyuu, ttriaqfrnz - zmfuwsjpaa)
-
16 Oct 2023
(Experimental: Etrasimod 2 mg)
hfsfynubnw(acnrgwhhbp) = rpiruweppw qguxgpdvgm (uxvxnviyuu, mckijhzdpk - hhmibmathh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free